Author/Authors :
Pompili, Maurizio Department of Neurosciences - Unit of Psychiatry - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy , Corigliano, Valentina Department of Neurosciences - Unit of Psychiatry - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy , Comparelli, Anna Department of Neurosciences - Unit of Psychiatry - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy , Mancinelli, Iginia Department of Neurosciences - Unit of Psychiatry - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy , Montalbani, Benedetta Department of Neurosciences - Unit of Psychiatry - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy , Erbuto, Denise Department of Neurosciences - Unit of Psychiatry - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy , Girardi, Paolo Department of Neurosciences - Unit of Psychiatry - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy , Lamis, Dorian A. Department of Psychiatry and Behavioral Sciences - Emory School of Medicine - Grady Hospital - Atlanta - GA, USA , De Carolis, Antonella Department of Neurosciences - Unit of Neurology - Sapienza University of Rome - School of Medicine and Psychology - Via di Grottarossa - Rome, Italy
Abstract :
Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patientswith chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patientswith early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-termdiagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patientsreceiving LAI-SGA with 5 or less years of illness duration (n= 10) were compared to those with more than 5 years of illnessduration (n= 15). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment ofFunctioning(GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greaterimprovement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negativeand depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis thatLAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies areneeded, possibly with larger samples
Keywords :
Long-Acting , Injectable , Second-Generation , Antipsychotics Improve Negative Symptoms , Suicidal Ideation , Recent Diagnosed Schizophrenia Patients , A 1-Year Follow-up Pilot Study , Long-acting injectable second-generation antipsychotics (LAI-SGA) , MSCEIT
